Subsequent anticancer therapy analysis of the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Background and Aims: In the Phase 3 HIMALAYA study (NCT03298451), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) vs sorafenib in participants (pts) with unresectable hepatocellular carcinoma (uHCC; Abou-Alfa et al. NEJM Evid 2022). The OS benefit with STRIDE persisted after 5 years of follow-up (OS HR 95% confidence interval [CI] vs sorafenib, 0.76 [0.65–0.89]; Rimassa et al. oral presentation (974MO) at ESMO 2024). Assessment of subsequent anticancer therapy (SAT) use is key to understanding the long-term benefits and outcomes of STRIDE. Here, we report the assessment of SAT use at the 5-year follow-up.